Lahoor Basha Shaik, Suresh Sake, Ashok Reddy V V, Surya Teja S P
Department of Medical Affairs, HealthMinds, Bengaluru, Karnataka, 560038, India.
Department of General Medicine, Andaman & Nicobar Health Services, Port Blair, 744104, India.
Clin Epidemiol Glob Health. 2021 Jan-Mar;9:326-331. doi: 10.1016/j.cegh.2020.10.005. Epub 2020 Oct 21.
Despite being announced as a global health concern and emergency in January by WHO, designing specific treatment for SARS-CoV-2 is still a summit yet to be conquered. Currently, many drugs are being tested in the clinical scenario and vitamins play a significant role in therapeutic management. Based on the available evidence, we postulate that maintaining normal vitamin D levels may reduce severity, mortality risk of COVID-19. This review elucidates the alarming need for randomized clinical trials to determine the role of vitamin D in patient prognosis in COVID-19 infection and on latitude bases epidemiological outcome.
尽管世界卫生组织在1月份宣布新型冠状病毒肺炎为全球卫生关注重点和紧急情况,但设计针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的特异性治疗方法仍是一个有待攻克的难题。目前,许多药物正在临床环境中进行测试,维生素在治疗管理中发挥着重要作用。基于现有证据,我们推测维持正常的维生素D水平可能会降低新型冠状病毒肺炎的严重程度和死亡风险。这篇综述阐明了迫切需要进行随机临床试验,以确定维生素D在新型冠状病毒肺炎感染患者预后以及基于纬度的流行病学结果中的作用。